The United States Department of Agriculture has issued a conditional license for Feline Interleukin-2 Immunomodulator, Live Canarypox Vector produced by Merial, Inc. The conditional license requires a product to be pure, safe, and have an expectation of efficacy and will expire in two years. Several studies have been performed to determine the safety of the vaccine.
The Feline Interleukin-2 Immunomodulator, Live Canarypox Vector vaccine is designed to be used post surgical removal of feline fibrosarcoma. The vaccine will be made available to licensed veterinarians and is “for use by or under the supervision of a veterinarian”.
No comments:
Post a Comment